Apollo Endosurgery Inc (NASDAQ:APEN) CEO Todd Newton purchased 25,000 shares of the company’s stock in a transaction on Friday, May 10th. The shares were purchased at an average cost of $3.53 per share, with a total value of $88,250.00. Following the purchase, the chief executive officer now owns 317,668 shares of the company’s stock, valued at $1,121,368.04. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of NASDAQ APEN traded up $0.10 during midday trading on Friday, reaching $3.83. The company had a trading volume of 520 shares, compared to its average volume of 13,738. Apollo Endosurgery Inc has a one year low of $3.02 and a one year high of $9.65. The company has a current ratio of 2.77, a quick ratio of 2.24 and a debt-to-equity ratio of 1.33. The firm has a market cap of $86.81 million, a PE ratio of -1.99 and a beta of 0.75.
Apollo Endosurgery (NASDAQ:APEN) last released its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.02). Apollo Endosurgery had a negative net margin of 69.37% and a negative return on equity of 97.89%. The company had revenue of $13.21 million during the quarter, compared to the consensus estimate of $13.21 million. As a group, equities research analysts forecast that Apollo Endosurgery Inc will post -1.57 earnings per share for the current fiscal year.
Several equities research analysts have issued reports on the company. Zacks Investment Research lowered Apollo Endosurgery from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. ValuEngine lowered Apollo Endosurgery from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. purchased a new position in shares of Apollo Endosurgery during the 1st quarter worth approximately $64,000. Gagnon Securities LLC boosted its position in shares of Apollo Endosurgery by 1.4% during the 1st quarter. Gagnon Securities LLC now owns 863,160 shares of the biotechnology company’s stock worth $3,228,000 after purchasing an additional 11,534 shares during the period. NJ State Employees Deferred Compensation Plan boosted its position in shares of Apollo Endosurgery by 8.3% during the 1st quarter. NJ State Employees Deferred Compensation Plan now owns 130,000 shares of the biotechnology company’s stock worth $486,000 after purchasing an additional 10,000 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Apollo Endosurgery by 5.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 123,117 shares of the biotechnology company’s stock worth $425,000 after purchasing an additional 6,551 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of Apollo Endosurgery during the 4th quarter worth approximately $41,000. 39.28% of the stock is owned by institutional investors.
About Apollo Endosurgery
Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults.
Featured Story: Fundamental Analysis
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.